High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored?

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Lugade, Amit A ^a   Kalathil, Suresh ^a   Miller, Austin ^a   Iyer, Renuka ^a   Thanavala, Yasmin ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

GARP; Granzyme B; HCC; MDSCs; Tregs

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR FOXP3;

ADVANCED CANCER; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL KILLING; CELL LINE; CELL METABOLISM; CELL POPULATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; EFFECTOR CELL; ENZYME SYNTHESIS; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VITRO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T CELL DEPLETION; T LYMPHOCYTE; TARGET CELL; TREATMENT RESPONSE; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME;

EID: 84886945035     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24679     Document Type: Article

References (10)

1. Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP+ CTLA-4+ Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T cell functionality. Cancer Res, 2013; 73:2435-44; PMID:23423978; http://dx.doi. org/10.1158/0008-5472.CAN-12-3381
2. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 2005; 65:2457-64; PMID:15781662; http://dx.doi. org/10.1158/0008-5472.CAN-04-3232
3. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res, 2009; 69:3995-4000; PMID:19383912; http://dx.doi. org/10.1158/0008-5472.CAN-08-3804
4. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci, U S A 2009; 106:13439-44; PMID:19666573
5. Laurent C, Müller S, Do C, Al-Saati T, Allart S, Larocca LM, et al. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood, 2011; 118:5371-9; PMID:21856865; http://dx.doi.org/10.1182/blood- 2011-04-345777
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
8. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr., et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med, 2012; 4:34ra62; PMID:22593175; http://dx.doi. org/10.1126/scitranslmed.3003330
9. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res, 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078- 0432.CCR-08-1332
10. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res, 2008; 14:6674-82; PMID:18927310; http://dx.doi. org/10.1158/1078-0432.CCR-07-5212